DCN Dx Acquires BioSouthTech to Expand Biospecimen Access in Latin America
DCN Dx has announced the acquisition of BioSouthTech, Inc., a Miami-based human biospecimen provider. The move significantly expands DCN Dx's collection network into Latin America and the Caribbean, providing access to more diverse patient populations and banked specimens. The acquisition is strategically aimed at supporting developers of liquid biopsy assays, such as multi-cancer early detection (MCED) and measurable residual disease (MRD) tests. By increasing specimen diversity across oncology, neurology, and autoimmune research, DCN Dx aims to help diagnostic companies improve test performance and representation across different ancestries.
Topics: Biospecimen acquisition Healthcare expansion Latin American market access Oncology research